Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies ...

Finally this week, TORL BioTherapeutics completed a $96 million Series C that will be deployed in the development of its lead ...

At LSX in Boston last month, editor-in-chief Jonah Comstock spoke with Teresa Whalen, the CEO of CytoAgents, a clinical-stage ...

In the latest 10-year plan for the NHS, the UK government has laid out a plan to invest £120 million in 85 mental health ...

GoodRx contends that adding its discounting programmes to TrumpRx could expand the scheme so it is more useful for the insured, in addition to under- and uninsured people, and also raise the prospect ...

Karen Westaway is CEO of ValueBase. She is a health equity evangelist passionate about accelerating access to innovative medicines. ValueBase works with global and EU partners across industry and ...

AZ revealed its $50 billion investment programme in July, in the midst of industry concerns about threatened tariffs on pharmaceutical imports into the US – now set to come into effect with a base ...

In drug development, that means showing how models are trained, which data are used, and how predictions of safety and ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis ...

The regulatory authorities in the UK and US have agreed to work more closely together on the regulation of medical ...

Sanofi raised its interest in AlphaMedix when it bought a 16% stake in Orano Med, a subsidiary of French nuclear fuel company ...

A jury in a Los Angeles, California court has ordered the company to pay an eye-watering $966 million to the family of Mae ...